Interferon Beta-1b (rIFN-B)(in ter feer’ on)
Betaseron, Extavia
PREGNANCY CATEGORY C
Drug Classes
Immunomodulator
Interferon
MS drug
Therapeutic Actions
Interferons are produced by human leukocytes in response to viral infections and other stimuli; interferon beta-1b block replication of viruses and stimulate the host immunoregulatory activities. Interferon beta-1b is produced by recombinant DNA technology using Escherichia coli.
Indications
Reduce the frequency of clinical exacerbations in relapsing, remitting MS
Contraindications and Cautions
Contraindicated with allergy to beta interferon, human albumin, or product components; lactation.
Use cautiously with chronic progressive MS, suicidal tendencies, mental disorders, pregnancy.
Available Forms
Powder for injection—0.3 mg
Dosages
Adults
0.25 mg subcutaneously every other day; discontinue use if disease is unremitting for more than 6 mo. Initially, 0.0625 mg subcutaneously every other day, weeks 1–2; then 0.125 mg subcutaneously every other day, weeks 3–4; 0.1875 mg subcutaneously every other day, weeks 5–6; target 0.25 mg subcutaneously every other day by week 7.
Pediatric patients
Safety and efficacy not established in patients younger than 18 yr.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
